Company / SG&A Expense
Revolution Medicines, Inc. SG&A Expense History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$195.0M
FY2025
5-year range
$12.4M / $195.0M
FY2021-FY2025
Trend
+100.5%
vs FY2024
Sector context
#70 of 213
Health Care
What the data says
At $195M, Revolution Medicines, Inc.'s sg&a expense ranks #144 of 213 in the Health Care sector. SG&A Expense has increased for 5 consecutive years, from $9M in FY2020 to $195M in FY2025.
Based on SEC 10-K filings.
$195M in FY2025 with a 5-year CAGR of +83.4%.
Increased from $76M to $195M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +108.8%
- 5-Year CAGR
- +83.4%
- 10-Year CAGR
- -
Sector benchmark
#144 of 213 in Health CareTop 67% of 213This company $195.0M Sector average $722.3M
▼
-73.0% below sector average
Key checks
Key Insights
- Revolution Medicines, Inc.'s sg&a expense has grown for 5 consecutive years.
- 5-year CAGR of +83.4%, indicating consistent growth.
- In FY2025, sg&a expense increased 100.5% year-over-year.
- Ranks #70 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -1.10 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $195.0M | +100.5% |
| FY2024 | $97.3M | +28.7% |
| FY2023 | $75.6M | +252.9% |
| FY2022 | $21.4M | +72.7% |
| FY2021 | $12.4M | +31.8% |
| FY2020 | $9.4M | -24.1% |
| FY2019 | $12.4M | +31.8% |
| FY2018 | $9.4M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026